Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study

NCT07657299 | Completed DMC

• 2 other identifiers: FMASU MS 332/2022URO 37 12 28
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Bladder cancer is common tumor in which recurrence and/or progression in patients undergoing TUR has been reported to range between 30% and 80% in patients with NMIBC TCC. With evidence of E-cadherin, β-catenin and SOX4 playing a role in the development of tumors, it manifests as invasion and metastasis. In this study, we hope to develop the correlation regarding the alternation in the expression of E-cadherin, β-catenin and Sox4 in determining the recurrence, progression and up staging and their prognostic value in NMIBC.

Conditions

Bladder Cancer; Bladder Cancer Recurrence

Keywords

β-catenin, E-cadherin, NMIBC, progression, recurrence, SOX4

Outcome Measures

Primary Outcomes (1)

• This study aims to develop correlation regarding the alternation in the expression of E-cadherin, β-catenin and SOX4 in determining the recurrence and/or progression and their prognostic value in NMIBC TCC.

  This study aims to develop correlation regarding the alternation in the expression of E-cadherin, β-catenin and SOX4 in determining the recurrence and/or progression and their prognostic value in NMIBC TCC.

  2 years

Study Arms (1)

30 patients who treated with transurethral resection of bladder tumor finally diagnosed with NMIBC

* Inclusion Criteria: 1. The patients were treated with transurethral resection of bladder tumor finally diagnosed with NMIBC TCC by pathological examination. 2. The controls were normal bladder tissues. Or patients diagnosed with cystitis or dysplasia on pathological examination * Exclusion Criteria: 1. Age at the time of cancer diagnosis \> 70 years 2. Patients diagnosed with MIBC 3. Patients with concomitant upper urinary tracts tumors 4. Patients with concomitant prostatic tumors 5. Patients diagnosed with TCC T1 who did not received full induction, or maintenance doses BCG 6. Patients showed BCG toxicity signs 7. Patients diagnosed with TCC T1 who did not underwent 2nd look TURBT 8. Patients with known genetic/congenital disorder that may interfere with/or increase risk of BC; * Bladder exstrophy. * Rb1: An altered form of Rb1, retinoblastoma gene, is associated with cancer of the eye in infants,

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

* Inclusion Criteria: 1. The patients were treated with transurethral resection of bladder tumor finally diagnosed with NMIBC TCC by pathological examination. 2. The controls were normal bladder tissues. Or patients diagnosed with cystitis or dysplasia on pathological examination * Exclusion Criteria: 1. Age at the time of cancer diagnosis \> 70 years 2. Patients diagnosed with MIBC 3. Patients with concomitant upper urinary tracts tumors 4. Patients with concomitant prostatic tumors 5. Patients diagnosed with TCC T1 who did not received full induction, or maintenance doses BCG 6. Patients showed BCG toxicity signs 7. Patients diagnosed with TCC T1 who did not underwent 2nd look TURBT 8. Patients with known genetic/congenital disorder that may interfere with/or increase risk of BC; 9. Patients with history of chemotherapy or pelvic radiations for other tumor treatment than BC

You may qualify if:

• \. The patients were treated with transurethral resection of bladder tumor finally diagnosed with NMIBC TCC by pathological examination.
• \. The controls were normal bladder tissues. Or patients diagnosed with cystitis or dysplasia on pathological examination

You may not qualify if:

• Age at the time of cancer diagnosis \> 70 years
• Patients diagnosed with MIBC
• Patients with concomitant upper urinary tracts tumors
• Patients with concomitant prostatic tumors
• Patients diagnosed with TCC T1 who did not received full induction, or maintenance doses BCG
• Patients showed BCG toxicity signs
• Patients diagnosed with TCC T1 who did not underwent 2nd look TURBT
• Patients with known genetic/congenital disorder that may interfere with/or increase risk of BC;
• Bladder exstrophy.
• Rb1: An altered form of Rb1, retinoblastoma gene, is associated with cancer of the eye in infants, and may increase your bladder cancer risks.
• Cowden disease: This syndrome, linked to an abnormal form of the gene PTEN, may trigger breast cancer and thyroid cancer, and increases the risk of bladder cancer.
• Lynch syndrome: This genetic condition, also known as hereditary non-polyposis colorectal cancer, is usually tied to colon and endometrial cancer. However, this syndrome may also increase the risk of bladder cancer and cancer of the ureter.
• Patients with history of chemotherapy or pelvic radiations for other tumor treatment than BC

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Faculty of medicine, Ain Shams University

Cairo, Abbasia, Egypt

Location

Related Publications (20)

• Du Y, Spence SE, Jenkins NA, Copeland NG. Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood. 2005 Oct 1;106(7):2498-505. doi: 10.1182/blood-2004-12-4840. Epub 2005 Jun 16.

  PMID: 15961513 BACKGROUND

• Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, Shortliffe L, Weissman IL. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21. doi: 10.1073/pnas.0906549106. Epub 2009 Aug 4.

  PMID: 19666525 BACKGROUND

• Ojha R, Singh SK, Bhattacharyya S, Dhanda RS, Rakha A, Mandal AK, Jha V. Inhibition of grade dependent autophagy in urothelial carcinoma increases cell death under nutritional limiting condition and potentiates the cytotoxicity of chemotherapeutic agent. J Urol. 2014 Jun;191(6):1889-98. doi: 10.1016/j.juro.2014.01.006. Epub 2014 Jan 15.

  PMID: 24440234 BACKGROUND

• Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schubeler D, van Nimwegen E, Christofori G. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell. 2013 Jun 10;23(6):768-83. doi: 10.1016/j.ccr.2013.04.020.

  PMID: 23764001 BACKGROUND

• Lioubinski O, Muller M, Wegner M, Sander M. Expression of Sox transcription factors in the developing mouse pancreas. Dev Dyn. 2003 Jul;227(3):402-8. doi: 10.1002/dvdy.10311.

  PMID: 12815626 BACKGROUND

• Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009 Jun;28(1-2):15-33. doi: 10.1007/s10555-008-9169-0.

  PMID: 19169796 BACKGROUND

• Kashibuchi K, Tomita K, Schalken JA, Kume H, Takeuchi T, Kitamura T. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol. 2007 Sep;14(9):789-94. doi: 10.1111/j.1442-2042.2007.01830.x.

  PMID: 17760743 BACKGROUND

• Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, Schalken JA. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer. 1997 Aug 22;74(4):374-7. doi: 10.1002/(sici)1097-0215(19970822)74:43.0.co;2-s.

  PMID: 9291424 BACKGROUND

• Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 1993 Jul 15;53(14):3241-5.

  PMID: 8324734 BACKGROUND

• Lorusso V, Silvestris N. Systemic chemotherapy for patients with advanced and metastatic bladder cancer: current status and future directions. Ann Oncol. 2005 May;16 Suppl 4:iv85-89. doi: 10.1093/annonc/mdi914. No abstract available.

  PMID: 15923437 BACKGROUND

• Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S; West Midlands Urological Research Group. Delay and survival in bladder cancer. BJU Int. 2002 Jun;89(9):868-78. doi: 10.1046/j.1464-410x.2002.02776.x.

  PMID: 12010230 BACKGROUND

• van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009 Sep;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028. Epub 2009 Jun 26.

  PMID: 19576682 BACKGROUND

• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000 Jan;163(1):73-8. doi: 10.1016/s0022-5347(05)67975-x.

  PMID: 10604317 BACKGROUND

• Oosterlinck W. The management of superficial bladder cancer. BJU Int. 2001 Jan;87(2):135-40. doi: 10.1046/j.1464-410x.2001.00948.x. No abstract available.

  PMID: 11167630 BACKGROUND

• Aine M, Eriksson P, Liedberg F, Hoglund M, Sjodahl G. On Molecular Classification of Bladder Cancer: Out of One, Many. Eur Urol. 2015 Dec;68(6):921-3. doi: 10.1016/j.eururo.2015.07.021. Epub 2015 Jul 26.

  PMID: 26215606 BACKGROUND

• EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.

  BACKGROUND

• Shimazui T, Schalken JA, Giroldi LA, Jansen CF, Akaza H, Koiso K, Debruyne FM, Bringuier PP. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res. 1996 Sep 15;56(18):4154-8.

  PMID: 8797585 BACKGROUND

• Kiriluk KJ, Prasad SM, Patel AR, Steinberg GD, Smith ND. Bladder cancer risk from occupational and environmental exposures. Urol Oncol. 2012 Mar-Apr;30(2):199-211. doi: 10.1016/j.urolonc.2011.10.010.

  PMID: 22385990 BACKGROUND

• Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009 Jun;27(3):289-93. doi: 10.1007/s00345-009-0383-3. Epub 2009 Feb 15.

  PMID: 19219610 BACKGROUND

• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29. doi: 10.3322/canjclin.48.1.6.

  PMID: 9449931 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Cystoscopic Bladder mass biopsies

MeSH Terms

Conditions

Urinary Bladder Neoplasms; Non-Muscle Invasive Bladder Neoplasms; Disease Progression; Recurrence

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 13, 2026
• First Posted: June 18, 2026
• Study Start: April 1, 2022
• Primary Completion: June 1, 2024
• Study Completion: June 1, 2024
• Last Updated: June 18, 2026

Record last verified: 2026-01

Locations

EG (1)